Loading
Vericel Corp Stock: price and insider trades · United States
Vericel Corp: what insiders have been doing
Headquartered in Cambridge, United States, Vericel Corp belongs to the Healthcare & Pharma sector and traces its origins to 1989. Filings by its managers are published through SEC (Form 4). Between 18 October 2025 and 18 October 2026, 19 insiders published 61 filings.
Only sales appear on the open market, 14 sales in all totalling €1.7M, filed by 7 insiders. No amount is published for 4 filings, which the totals therefore leave out. At €406k, the sale published on 5 August 2026 by Halpin Michael is the largest of the period (0.023% of market cap).
The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
For context, the typical company on the same exchange (median of 5,810 companies) published 19 filings over the same period, against 61 filings here. Our records for Vericel Corp go back to 2021, with no purchases and 36 sales on the open market in total. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 276.3 m USD and net income at 16.5 m USD.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
231
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€4M
36 ops. · all time
Who traded when
BuySaleJonathan Siegal4 sales
Joseph Anthony Mara Jr.3 sales
Sean C. Flynn3 sales
Jonathan Mark Hopper2 sales
Michael Halpin2 sales
Wotton Paul K2 sales
+1 other insider
Analyst consensus: bullish or bearish?
Analysts rate Vericel Corp Strong Buy (bullish), based on 7 analysts. Average price target: US$59.71.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 13,123 of 24,148 companies
49.1
score / 100
Value41
Quality57
FCF yld1.2%
Earn yld0.8%
EV/EBITDA·
ROE7.2%
Gross mgn74%
Net mgn6.0%
Debt/EBITDA3.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$40.25
Analyst consensus
7 analystsStrong buy
US$52.00Target US$59.71(+48%)US$72.00
Income statement
RevenueUS$276.3M
Gross profitUS$205.6M74% margin
EBITDAUS$29.6M11% margin
Net incomeUS$16.5M7.9% margin
Valuation
PER (trailing)85.6x
PER (forward)47.6x
P/Book5.6x
Beta1.03
Balance sheet & cash
Market capUS$2.1B
Total debtUS$96.4M
Free Cash FlowUS$24.7M
Debt / Equity25%
Profitability & ownership
ROE7.2%
ROA2.4%
% insiders1.2%
% institutions110.4%
Last declaration on 14 August 2026
Declarations231 total
7,000 shares@ US$13.050.0045% mcap10.5% of flowCommon StockSEC:0001140361-26-033143:0
7,000 shares@ US$44.530.015% mcap35.9% of flowCommon StockSEC:0001140361-26-033143:1
7,000 shares@ US$44.110.015% mcap35.5% of flowCommonSEC144:0001959173-26-005916
10,000 shares@ US$46.840.023% mcap15.6% of flowCommon StockSEC:0001140361-26-031417:1
10,000 shares@ US$16.660.0082% mcap5.6% of flowCommon StockSEC:0001140361-26-031417:0
10,000 shares@ US$45.980.023% mcap15.3% of flowCommonSEC144:0001959173-26-005511
2,500 shares@ US$48.900.0060% mcap9.8% of flowCommon StockSEC:0001140361-26-030487:3
2,500 shares@ US$29.820.0037% mcap6.0% of flowCommon StockSEC:0001140361-26-030487:2
1,500 shares@ US$34.900.0026% mcap4.2% of flowCommon StockSEC:0001140361-26-030487:0
1,500 shares@ US$48.900.0036% mcap5.9% of flowCommon StockSEC:0001140361-26-030487:1
500 shares@ US$29.820.0007% mcap1.2% of flowCommon StockSEC:0001140361-26-030487:4
500 shares@ US$48.900.0012% mcap2.0% of flowCommon StockSEC:0001140361-26-030487:5
4,500 shares@ US$48.900.011% mcap17.6% of flowCommonSEC144:0001959173-26-005454
5,000 sharesCommon StockSEC:0001140361-26-026931:0
15,000 sharesCommon StockSEC:0001140361-26-026929:0
15,000 sharesCommon StockSEC:0001140361-26-026929:1
5,000 sharesCommon StockSEC:0001140361-26-026930:0
5,000 sharesCommon StockSEC:0001140361-26-026930:1
5,000 sharesCommon StockSEC:0001140361-26-026930:2
5,000 sharesCommon StockSEC:0001140361-26-026930:3
15,000 shares@ US$45.64390.029% mcap24.0% of flowCommonSEC144:0001959173-26-004925
10,000 shares@ US$45.000.019% mcap24.9% of flowCommonSEC144:0001959173-26-004921
5,000 shares@ US$44.750.0094% mcap19.2% of flowCommonSEC144:0001959173-26-004924
2,732 shares@ US$44.900.0051% mcap9.9% of flowCommonSEC144:0001959173-26-004922
15,000 shares@ US$40.20990.025% mcap20.9% of flowCommonSEC144:0001959173-26-004780
25 of 231 declarations
About Vericel Corp
Vericel Corp. (NASDAQ:VCEL) is a United States-based commercial-stage biotechnology and regenerative medicine company listed on the NASDAQ market in the United States. Headquartered in Cambridge, Massachusetts, United States, the company has evolved from its origins as Aastrom Biosciences into a focused specialty biologics platform centered on autologous cell therapies for highly specialized, high-value indications. The modern Vericel story took shape after the 2014 rebranding, when the company shifted toward marketed products and away from a pure development-stage profile. ([investors.vcel.com](https://investors.vcel.com/news-releases/news-release-details/aastrom-biosciences-changes-name-vericel-corporation?utm_source=openai))
Vericel’s business is organized around three core products. MACI is the flagship franchise and is used for the repair of symptomatic cartilage defects in the knee through an autologous cell therapy approach. Epicel is a permanent skin replacement product for patients with deep dermal or full-thickness burns, giving Vericel a niche position in severe burn care. NexoBrid, licensed for North American commercial rights, extends the portfolio into enzymatic debridement for severe thermal burns. Together, these products place Vericel in a highly specialized segment with meaningful regulatory barriers, complex manufacturing requirements, and strong relationships with orthopedic and burn centers. ([vcel.com](https://www.vcel.com/about/?utm_source=openai))
Read moreShow less
From a competitive standpoint, Vericel stands out because very few companies have comparable exposure to both sports-medicine cartilage repair and severe burn treatment. The company emphasizes its autologous-cell-therapy expertise, its deep commercial infrastructure in the United States, and its manufacturing know-how as key differentiators. A major strategic development is the new manufacturing and corporate headquarters facility in Burlington, Massachusetts, which was built to expand cell-therapy capacity and support long-term growth for MACI and Epicel. Recent company communications indicate the facility is complete and commercial manufacturing is expected to begin in 2026. ([investors.vcel.com](https://investors.vcel.com/news-releases/news-release-details/vericel-announces-plans-new-state-art-cell-therapy-manufacturing?utm_source=openai))
For investors, the appeal lies in MACI’s commercial visibility, the relatively defensible nature of Vericel’s niche markets, and the operational upside from additional manufacturing capacity. The company’s 2025 updates highlighted strong revenue momentum and improved profitability, supported by MACI and increasing contribution from NexoBrid in burn care. As a NASDAQ-listed U.S. healthcare small cap, Vericel offers a concentrated product mix, a clear strategic focus, and a primarily domestic commercial footprint. ([investors.vcel.com](https://investors.vcel.com/news-releases/news-release-details/vericel-reports-first-quarter-2025-financial-results-and-raises?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
